Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 niraparib study in DNA-repair-anomalous metastatic castration-resistant prostate cancer
NL-OMON50358Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective response rate in BRCA cohort and Objective response rate overall. Started Feb 2018; status: completed.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON50358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50358.